TB006 is a new drug showing huge potential in the treatment of Alzheimer’s disease.
Clinical trials have shown the drug not only slows disease progression—it can also reverse signs of the devastating condition.
But is this a miracle treatment? Or are there nasty TB006 side effects to consider?
This article explores the possible side effects of TB006 based on the latest clinical research.
It also explains how to manage these adverse effects and what further research is needed.
As with any new medication, understanding common TB006 side effects is crucial for ensuring drug safety.
So far, research suggests no major side effects related to TB006.
Phase 1 clinical trials in 2021, which tested the drug's safety and side effects in healthy adults, concluded that “side effects were generally mild.”
A later clinical trial tested TB006 in people with Alzheimer’s disease. Once again, no serious adverse effects were seen among patients.
That said, no medication is completely free from potential side effects. For TB006, an infusion reaction is the most commonly reported side effect in clinical trials.
An infusion reaction occurs when your body responds negatively to a medication given directly into the bloodstream through an intravenous injection.
This happens because, in some cases, the immune system mistakenly identifies the medication as harmful and attempts to fight it off.
With TB006, infusion reactions can occur because the drug is delivered directly into the blood via a vein. Fortunately, these reactions are usually mild, causing symptoms like fever, rash, or nausea.
These adverse effects typically subside within 30 to 120 minutes after the infusion ends.
In rare cases, infusion reactions can be more severe, leading to low blood pressure, dizziness, or breathing difficulties.
However, our expert medical team carefully monitors patients throughout the infusion process and can slow or stop the infusion if necessary to manage these symptoms.
As TB006 is still in the experimental stages, there is limited data on long-term TB006 side effects.
Current studies have focused on the drug's short-term safety and effectiveness, with results showing promising outcomes and minimal side effects.
Ongoing clinical trials are necessary to understand the potential long-term impact on Alzheimer’s patients—and these are underway as we speak.
TrueBinding started a trial in 2022 that is looking at the long-term safety of TB006 in Alzheimer’s patients, including longer-term adverse effects.
It’s essential for patients and caregivers to stay informed about the latest research and consult healthcare providers about any concerns related to long-term use.
Q: What should I do if I experience an infusion reaction during TB006 treatment?
A: If you experience symptoms like fever, chills, or a rash during an infusion, alert your healthcare provider. They can manage these reactions by adjusting the infusion rate.
Q: Are the side effects of TB006 severe?
A: Most side effects associated with TB006 are mild, such as infusion reactions. They are generally short-lived and usually subside shortly after the infusion is complete.
Q: Can TB006 cause long-term side effects?
A: The long-term side effects of TB006 are not yet fully known, as the drug is still under study. Ongoing research aims to understand any potential long-term risks.
TB006 is a promising treatment for Alzheimer’s disease, with the potential to slow or even reverse the condition—and with minimal adverse effects.
Nevertheless, while most TB006 side effects are mild and manageable, it’s crucial to stay informed about the ongoing research and any updates on safety.
If you or a loved one is considering TB006, our team at Universal Neurological Care is here to provide comprehensive support and guidance.
Contact us today to learn more about this breakthrough Alzheimer’s treatment, the cost of TB006, and how it could fit into your treatment plan.
